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ABSTRACT 
Orodispersible tablets (ODTs), also known as fast melt, quick melts, fast disintegrating have the unique property of disintegrating in 
the mouth in seconds without chewing and the need of water. The purpose of this investigation was to develop mouth dissolving 
tablets of Lornoxicam using KYRON T-314 (Polacrillin Potassium) as a novel superdisintegrant. Mouth dissolving tablets of 
lornoxicam were prepared by wet granulation technique using KYRON T-314 as superdisintegrant and menthol as subliming agent. 
The present study demonstrated potentials for rapid absorption, improved bioavailability, effective therapy and patient compliance. 
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The tablet is the most widely used dosage form because of 
its convenience in terms of self administration, 
compactness and ease in manufacturing. However, 
geriatric and pediatric patients experience difficulty in 
swallowing conventional tablets, which leads to poor 
patient compliance. To overcome this weakness, scientists 
have developed innovative drug delivery systems known as 
mouth dissolving tablets. Their characteristic advantages 
such as administration without water, anywhere, anytime 
lead to their suitability to geriatric and pediatric patients. 
They are also suitable for the mentally ill, the bedridden 
and patients who do not have easy access to water. The 
benefits, in terms of patient compliance, rapid onset of 
action, increased bioavailability and good stability made 
these tablets popular as a dosage form in the current 
market1-2. NSAID has been indicated for various painful 
indications3 and proved as effective as other NSAIDs with 
lower indications of gastro-intestinal adverse effects and 
thus, resulted in a greater compliance with treatment4. 
Lornoxicam ,(2-[2-[2-(2,6 dichlorophenyl) aminophenyl] 
acetyl] oxyacetic acid), a nonsteroidal anti-inflammatory, 
analgesic and antipyretic drug used in rheumatoid arthritis, 
post-traumatic pain, masculo-skeletal and joint disorders5. 
Lornoxicam is practically insoluble. For poorly soluble 
orally administered drugs, the rate of absorption is often 
controlled by the rate of dissolution. The rate of dissolution 
can be increased by increasing the surface area of available 
drug by various methods (micronization, complexation and 
solid dispersion). 
The dissolution of a drug can also be influenced by 
disintegration time of the tablets. Faster disintegration of 
tablets delivers a fine suspension of drug particles resulting 
in a higher surface area and faster dissolution. Polacrillin 
Potassium (KYRON T- 314) is 2-methyl-2-propenoic acid 
polymer with divinylbenzene, potassium salt. It is a cation 
exchange resin used in oral pharmaceutical formulation as 
a tablet superdisintegrant. It appears as a cream colored, 
odorless and tasteless, free flowing powder6. 
In the present study, an attempt has been made to develop 
mouth dissolving tablets of lornoxicam using novel 
superdisintegrant and to investigate the effect of subliming 
agent on the release profile of the drug. The fundamental 
principle used in the development of the fast-dissolving 
tablet is to maximize its pore structure. Researchers have 
evaluated spray dried materials7 and plastic materials8 for 
development of such tablets. Vacuum-drying9-14 and freeze-
drying15-18 techniques have been also tried by researchers 
to maximize the pore structure of the matrix Freeze drying 
is cumbersome and yields a fragile and hygroscopic 
product. Therefore, a vacuum drying technique was 
adopted in the present investigation after addition of a 
subliming agent to increase porosity of the tablets. It is 
likely that a porous hydrophilic will easily pick up the 
disintegrating medium and break quickly. 
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MATERIAL AND METHODS 
Materials 
Lornoxicam and KYRON T-314 were obtained as a gift 
sample from Glenmark generics Ltd, Mumbai, India. 
Menthol, Magnesium stearate, Aspartame and Mannitol 





Formulation of Mouth Dissolving Tablets of 
Lornoxicam 
The orodispersible tablets of Lornoxicam were prepared 
using the subliming agent, menthol and KYRON T-314 as 
superdisintegrant, mannitol as diluent, aspartame as 
sweetening agent, alcoholic solution of polyvinyl 
pyrrolidone (PVP K-30) as binder and aerosil as flow 
promoter and magnesium stearate as lubricant, the 
composition of each batch is shown in Table 1. 
 
Table 1: Composition of different batches of mouth dissolving tablets of lornoxicam 
 INGREDIENTS QUANTITIES (mg) 
F1 F2 F3 F4 F5 
Lornoxicam  8  8  8  8  8 
Menthol  20  20  25  25  25 
Kyron T-314  20  20  20  25  25 
Mannitol  145  145  135  130  130 
PVP-K30 7  7  7  7  7 
aerosil  3  3  3  3  3 
Magnesium Sterate  2  2  2  2  2 
Total 200 200 200 200 200 
 
The raw materials were passed through a 100-mesh screen 
prior to mixing. The drug and other ingredients were 
mixed together and a sufficient quantity of alcoholic 
solution of PVP K-30 (10% w/v) was added and mixed to 
form a coherent mass. The wet mass was granulated using 
sieve no. 12 and regranulated after drying through sieve 
no. 16. Granules of the all formulations were then dried in a 
vacuum oven (Vertex, VT4810) at 60°C for 12 h resulting in 
localized drying. The final moisture content of the granules 
was found to be between 1-2%, which was determined 
using an IR moisture balance. During drying, the menthol 
sublimed with the formation of a porous structure on the 
surface of the tablet. The dried granules were then blended 
with talc, magnesium stearate and compressed into tablets 
using flat face round tooling on a Rimek-I rotary tablet 
machine (Karnavati Engg. Pvt. Ltd, Ahmedabad). 
Sublimation was performed from tablets instead of 
granules at 600C in selected batch (F5).  
Evaluation of formulated tablets: 
Thickness 
Thickness of tablet was determined by using vernier 
calliper (Mitutoya, Model CD-6 CS, Japan). 
Hardness19 
The crushing strength of the tablets was measured using a 
Monsanto hardness tester (Sheetal Scientific Industries, 
Mumbai, India). Three tablets from each formulation batch 
were tested randomly and the average reading noted. 
Friability19 
Twenty tablets were weighed and placed in a Roche 
friabilator (Electrolab, India). Twenty reweighed tablets 
were rotated at 25 rpm for 4 min. The tablets were then 
dedusted and reweighed and the percentage of weight loss 
was calculated. The percentage friability of the tablets were 
measured as per the following formula, 
                       
                           
             
      
Weight Variation 
Randomly, twenty tablets were selected after compression 
and the mean weight was determined. 
None of the tablets deviated from the average weight by 
more than ±7.5% (USPXX).  
 
Table 2: Evaluation of mouth-dissolving tablets of lornoxicam 
 
Parameters F1 F2 F3 F4 F5 
Hardness (kg/cm2) 3.1±0.30 3.4±0.68 2.9±0.51 3.1±0.63 3.6±0.10 
Friability (%) 0.743± 0.04 0.629± 0.06 0.637± 0.05 0.688±0.04 0.574±0.04 
Weight variation (mg) 204±3  199±2 203±3 197±1 200±1 
Thickness (mm) 3.5±0.03 3.4±0.07 3.6±0.05 3.4±0.06 3.5±0.01 
Wetting time (s) 38.2±2.5 39.3±1.5 43.6±2.2 39.1±2.0 29.4±1.5 
In-vitro dispersion time (s) 68.3±2  62.1±1  56.2±2  53.7±3  41.8±2 
Drug content 99.24± 3.24 98.44± 2.54 98.60±3.04 98.93±1.81 99.42±1.27 
Drug release in 5min (%) 69.03±2 72.17±2 73.72±2.5 75.54±3 78.37±1. 
Drug release in 30min (%) 86.81±1.2 88.11±1.6 88.73±2.5 93.26±2.7 97.25± 1.3 
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Wetting Time20 
A piece of circular tissue paper (8cm) folded twice was 
placed in a Petri dish (Internal Diameter = 9cm) containing 
10 ml of buffer solution simulating saliva pH 6.8. A tablet 
was placed on the paper and the time taken for complete 
wetting was noted. Three tablets from each formulation 
were randomly selected and the average wetting time was 
noted. The results are tabulated in Table 2. 
In vitro Dispersion Time21 
In vitro dispersion time of prepared tablet was done by 
dropping the tablet in 10 ml measuring cylinder containing 
6 ml of simulated salivary fluid (pH 6.8). Time required for 
complete dispersion of tablet was measured. 
Dissolution Study 
In vitro release of Lornoxicam from tablets was monitored 
by using 900 ml of simulated intestinal fluid, SIF (USP 
phosphate buffer solution, pH 7.4) at 37±0.5°C and 50 rpm 
using programmable dissolution tester [Paddle type, model 
TDT-08L, Electrolab, (USP), India]. 5 ml Aliquots were 
withdrawn at one minute time intervals and were 
replenished immediately with the same volume of fresh 
buffer medium. Aliquots, following suitable dilutions, were 
assayed spectrophotometrically (UV-1700, Shimadzu, 
Japan) at 378 nm. 
RESULTS AND DISCUSSION 
Mouth dissolving drug delivery is rapidly gaining 
acceptance as an important drug delivery technology. In 
such drug delivery, different dosage forms disintegrate 
rapidly in the patient’s mouth within a minute and can be 
gulped easily without need of water. This rapid 
disintegration can be achieved by use of high levels of 
disintegrant and/or effervescent agents along with water 
soluble diluents. Hence, it offers increased patient 
compliance and convenience. Water insoluble diluents 
such as microcrystalline cellulose and dicalcium phosphate 
were omitted from the study as they are expected to cause 
an unacceptable feeling of grittiness in the mouth. Among 
the soluble diluents, mannitol was selected as diluents 
considering its advantages in terms of easy availability and 
negative heat of dissolution.  
Table 2 shows that all the formulated tablets exhibited low 
weight variation. Addition of a subliming agent had no 
pronounced effect on hardness and increased friability of 
the tablets. The wetting time, in vitro dispersion time of the 
tablets were also considerably reduced in tablets (Table 2). 
The drug content of all the formulations was found to be 
between 98.4- 99.5% which was within the acceptable 
limits as per USP XXVII. The porous structure is 
responsible for faster water uptake; hence it facilitates 
wicking action of KYRON T-314 in bringing about faster 
disintegration. Tablets with lower friability may not break 
during handling on machines and/or shipping. The use of a 
sublimation agent resulted in increased friability probably 
due to increased porosity. In the first few attempts (F1-F4), 
sublimation of menthol was performed from granules prior 
to compression into tablets. Batches F1 to F4 showed good 
mechanical integrity, but the disintegration time was a 
little longer than the arbitrarily chosen value of less than 
50 seconds. In Batch F5, sublimation was performed after 
compression rather than directly from granules. The 
results shown in Table 2 reveal that sublimation of 
menthol from tablets resulted in faster disintegration. The 
compaction process might have caused breakage of porous 
granules and subsequent reduction in porosity. The low 
value of wetting time and disintegration time indicate that 
the porosity of tablets of batch F5 would be greater than 
batches F1 to F4. 
In vitro release studies were carried out using USP XXIII 
tablet dissolution test apparatus paddle method at 
37±10°C, taking 900 ml of simulated intestinal fluid (SIF) 
as dissolution medium. Speed of rotation of the paddle was 
set at 50 rpm. Aliquots of 5 ml were withdrawn after 1, 3, 
5, 6, 8, 10, 30 min and analyzed spectrophotometrically at 
274 nm. The in vitro dissolution profile indicated faster 
and maximum drug release from formulation F5. 
Formulation F5 prepared by direct sublimation of menthol 
from final tablets showed 78.37% drug release at the end 
of 5 min when compared to tablets prepared by 
sublimation of menthol from granules. The rapid drug 
dissolution might be due to easy breakdown of particles 
due to porous structure formation after sublimation of 
menthol and rapid absorption of drugs into the dissolution 
medium. 
CONCLUSION 
Polacrillin Potassium (KYRON T-314) is a cation exchange 
resin used in oral pharmaceutical formulation it swell 
rapidly when wetted. In the present study we used it as a 
novel super disintegrant and studied the effect of the effect 
of subliming agent on the release profile of the drug. From 
the outcome of this study, it can be concluded that 
sublimation method showed better disintegration and 
drug release. The prepared tablets using KYRON T-314 
disintegrate within few seconds without need of water; 
thereby enhancing the absorption leading to its increased 
bioavailability. Vacuum-drying technique would be an 
effective alternative approach compared with the use of 
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